9 Meters Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Equivalents	29.66	46.99	37.85	4.59	5.73	0.36	1.45	0.12	0.1
Short-Term Investments	0	0	0.08	0.08	0.08	0	0	0	0
Cash & Cash Equivalents	29.66	46.99	37.93	4.67	5.8	0.36	1.45	0.12	0.1
Cash Growth	-36.89%	23.91%	712.49%	-19.57%	1532.31%	-75.53%	1121.01%	22.68%	-
Receivables	0	0	0	0	0	0.08	0.86	0.64	3.57
Inventory	0	0	0	0	0	0	1.11	0.63	2.59
Other Current Assets	3.36	2.99	1	0.56	0.61	0.32	0.62	0.14	0.07
Total Current Assets	33.02	49.99	38.93	5.22	6.41	0.75	4.03	1.54	6.32
Property, Plant & Equipment	0.12	0.18	0.23	0.07	0.04	0.04	0	0	0
Goodwill and Intangibles	0	0	0	0	0	0	2.42	2.55	0
Other Long-Term Assets	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.63	0.09
Total Long-Term Assets	0.13	0.19	0.23	0.07	0.04	0.05	2.43	3.18	0.09
Total Assets	33.15	50.17	39.16	5.3	6.45	0.8	6.46	4.72	6.41
Accounts Payable	5.05	2.43	1.49	3.89	3.62	2.66	0.31	1.53	2.12
Current Debt	19.62	0	0.01	3.18	5.2	8.57	0.04	3.72	5.09
Other Current Liabilities	6.03	6.02	5.35	7.84	1.3	1.74	3.63	5.16	4.2
Total Current Liabilities	30.7	8.46	6.85	14.91	10.11	12.97	3.98	10.41	11.4
Long-Term Debt	0.05	0.11	0.17	0	0	0	0	0	0
Total Long-Term Liabilities	0.05	0.11	0.17	0	0	0	0	0	0
Total Liabilities	30.75	8.57	7.02	14.91	10.11	12.97	3.98	10.41	11.4
Total Debt	19.67	0.11	0.18	3.18	5.2	8.57	0.04	3.72	5.09
Debt Growth	17283.21%	-37.89%	-94.28%	-38.72%	-39.39%	22462.79%	-98.98%	-26.86%	-
Retained Earnings	-212.61	-168.84	-132.06	-70.56	-43.52	-19.35	-32.09	-25.88	-17.13
Shareholders' Equity	2.4	41.6	32.14	-9.61	-3.66	-12.17	2.49	-5.69	-4.99
Net Cash / Debt	9.99	46.88	37.74	1.48	0.61	-8.22	1.42	-3.6	-4.99
Net Cash / Debt Growth	-78.69%	24.20%	2444.65%	144.27%	-	-	-	-	-
Net Cash Per Share	0.77	3.86	7.15	0.89	0.49	-13.83	51.27	-218.64	-356.28
Working Capital	2.32	41.53	32.08	-9.69	-3.7	-12.22	0.06	-8.88	-5.08
Book Value Per Share	0.18	3.42	6.08	-5.77	-2.96	-20.48	90.14	-345.72	-356.20

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).